Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 040-046
DOI: 10.1055/s-0042-1742400
Review Article

Is Low-Dose Abiraterone for Prostate Cancer An Attractive Strategy for Limited Resource Settings?

Treshita Dey
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Shikha Goyal
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Kannan Periasamy
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Renu Madan
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Abiraterone acetate in combination with prednisone is approved for locally advanced as well as metastatic (hormone-sensitive and castrate-resistant) prostate cancer, with overall or disease-free survival gains in suitable patients. Long-term use poses a significant financial strain on the self-paying patients as well as the national health insurance schemes. Abiraterone is known to be a drug with a high “food effect” with increased bioavailability following high fat diet. Some retrospective series and phase 1 and 2 clinical studies have explored the use of low-dose abiraterone (at 25% of standard dose) with high fat meal with similar bioavailability and biochemical response to the standard drug dose. We review and report the available literature for this approach and discuss the financial and scientific implications of the same.

Keywords

prostate cancer - abiraterone acetate - low dose abiraterone - pharmacokinetics - PSA response

Authors' Contribution

T.D. contributed toward Concept, design, definition of intellectual content, literature search, data acquisition, data analysis, statistical analysis, manuscript preparation, and manuscript review. S.G. worked toward concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, and manuscript review. K.P. defined intellectual content and did data acquisition and manuscript review. R.M. contributed toward concept, design, literature search, data acquisition, data analysis, manuscript editing, and manuscript review.


Sources of Support

None.




Publication History

Article published online:
15 February 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ingrosso G, Detti B, Scartoni D. et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol 2018; 45 (5-6): 303-315
    CrossrefPubMedSearch in Google Scholar
  • 2 Central Drugs Standard Control Organisation, Directorate General Of Health Services. (Ministry of Health & Family Welfare, Government of India). Accessed December 07, 2021 at: https://cdscoonline.gov.in/CDSCO/Drugs
  • 3 United States Food and Drug Administration. Accessed December 07, 2021 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive
  • 4 Zytiga prescribing information. 2018 Accessed December 07, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202379s024lbl.pdf
    PubMedSearch in Google Scholar
  • 5 Schultz HB, Meola TR, Thomas N, Prestidge CA. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. Int J Pharm 2020; 577: 119069
    CrossrefPubMedSearch in Google Scholar
  • 6 Geboers S, Stappaerts J, Mols R. et al. The Effect of food on the intraluminal behavior of abiraterone acetate in man. J Pharm Sci 2016; 105 (09) 2974-2981
    CrossrefPubMedSearch in Google Scholar
  • 7 Center for Drug Evaluation and Research. Application number: 202379Orig1s000. Clinical pharmacology and biopharmaceutics review(s). Accessed December 07, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379orig1s000clinpharmr.pdf
  • 8 Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 2012; 69 (06) 1583-1590
    CrossrefPubMedSearch in Google Scholar
  • 9 Stuyckens K, Saad F, Xu XS. et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet 2014; 53 (12) 1149-1160
    CrossrefPubMedSearch in Google Scholar
  • 10 Chi KN, Spratlin J, Kollmannsberger C. et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol 2015; 55 (12) 1406-1414
    CrossrefPubMedSearch in Google Scholar
  • 11 Ryan CJ, Smith MR, Fong L. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28 (09) 1481-1488
    CrossrefPubMedSearch in Google Scholar
  • 12 Groenland SL, van Nuland M, Bergman AM. et al; Dutch Pharmacology Oncology Group (DPOG). Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. Eur J Cancer 2020; 130: 32-38
    CrossrefPubMedSearch in Google Scholar
  • 13 Meenu M, Sahoo RK, Seth A, Das U, Valpandian T, Arya DS. Food enhanced pharmacokinetics for clinical translation of low dose abiraterone acetate in metastatic castration-resistant prostate cancer. J Cancer Sci Clin Ther. 2020; 4 (03) 314-324
    CrossrefSearch in Google Scholar
  • 14 de Bono JS, Logothetis CJ, Molina A. et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21) 1995-2005
    CrossrefPubMedSearch in Google Scholar
  • 15 Petrioli R, Francini E, Fiaschi AI. et al. Reduced dose of abiraterone acetate with concomitant low-dose prednisone in the treatment of ≥ 85 year-old patients with advanced castrate-resistant prostate cancer. Anticancer Res 2015; 35 (05) 3097-3102
    Search in Google Scholar
  • 16 Leibowitz-Amit R, Seah JA, Atenafu EG. et al. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. Eur J Cancer 2014; 50 (14) 2399-2407
    CrossrefPubMedSearch in Google Scholar
  • 17 Szmulewitz RZ, Peer CJ, Ibraheem A. et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018; 36 (14) 1389-1395
    CrossrefPubMedSearch in Google Scholar
  • 18 Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ. Low-dose abiraterone with food: rebutting an editorial. J Clin Oncol 2018; 36 (30) 3060-3061
    CrossrefPubMedSearch in Google Scholar
  • 19 Ryan CJ, Smith MR, de Bono JS. et al; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (02) 138-148
    CrossrefPubMedSearch in Google Scholar
  • 20 Stein CA, Levin R, Given R. et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study. Urol Oncol 2018; 36 (02) 81.e9-81.e16
    CrossrefPubMedSearch in Google Scholar
  • 21 Solymosi T, Ötvös Z, Angi R. et al. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements. Int J Pharm 2017; 532 (01) 427-434
    CrossrefPubMedSearch in Google Scholar
  • 22 Goldwater R, Hussaini A, Bosch B, Nemeth P. Comparison of a novel formulation of abiraterone acetate vs. the originator formulation in healthy male subjects: two randomized, open-label, crossover studies. Clin Pharmacokinet 2017; 56 (07) 803-813
    CrossrefPubMedSearch in Google Scholar
  • 23 National Comprehensive Cancer Network Guidelines version 2. 2022 Accessed December 07, 2021 at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
    PubMedSearch in Google Scholar
  • 24 Tiako Meyo M, Alexandre J, Goldwasser F, Blanchet B. Low-dose abiraterone regimen: drug monitoring might be the key. J Clin Oncol 2018; 36 (30) 3061-3062
    CrossrefPubMedSearch in Google Scholar
  • 25 Fizazi K, Tran N, Fein L. et al; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377 (04) 352-360
    CrossrefPubMedSearch in Google Scholar
  • 26 Premnath N, Sedhom R, Gupta A. Potential cost savings with low-dose abiraterone in the United States. JCO Glob Oncol 2020; 6: 743-744
    CrossrefPubMedSearch in Google Scholar
  • 27 World Development Indicators - The World Bank Group. Accessed December 07, 2021 at: https://data.worldbank.org/country/india
  • 28 Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana (PM-JAY). Accessed December 07, 2021 at: https://pmjay.gov.in/
  • 29 Sydes MR, Spears MR, Mason MD. et al; STAMPEDE Investigators. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29 (05) 1235-1248
    CrossrefPubMedSearch in Google Scholar
  • 30 Persson U, Jönsson B. The end of the international reference pricing system?. Appl Health Econ Health Policy 2016; 14 (01) 1-8
    CrossrefPubMedSearch in Google Scholar
  • 31 Chiang CL, So TH, Lam TC, Choi HCW. Cost-effectiveness analysis of abiraterone acetate versus docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. Prostate Cancer Prostatic Dis 2020; 23 (01) 108-115
    CrossrefPubMedSearch in Google Scholar
  • 32 Patel A, Tannock IF, Srivastava P. et al. Low-dose abiraterone in metastatic prostate cancer: is it practice changing? Facts and facets. JCO Glob Oncol 2020; 6: 382-386
    CrossrefPubMedSearch in Google Scholar
  • 33 Serritella AV, Strohbehn GW, Goldstein DA, Lichter AS, Ratain MJ. Interventional pharmacoeconomics: a novel mechanism for unlocking value. Clin Pharmacol Ther 2020; 108 (03) 487-493
    CrossrefPubMedSearch in Google Scholar
  • 34 Peters N, Zameer MZ, O'Reilly S. Low-dose abiraterone, a rare European commodity. JCO Glob Oncol 2020; 6: 730
    CrossrefPubMedSearch in Google Scholar
  • 35 Szmulewitz RZ, Stadler WM, Ratain MJ. The abiraterone dosing chess match with Johnson & Johnson—back in check. JAMA Oncol 2021; 7 (06) 827-828
    CrossrefPubMedSearch in Google Scholar